文献速递系统性红斑狼疮

血小板LGALS3BP作为系统性红斑狼疮髓系炎症的介质

Platelet LGALS3BP as a Mediator of Myeloid Inflammation in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Rheumatol · 2023-03-14

研究对54例SLE患者和18名匹配健康对照的血小板进行RNA测序,发现SLE患者血小板LGALS3BP表达增加(倍数变化4.0,校正P=6.02×10⁻¹¹)。循环LGALS3BP与疾病活动度相关(r=0.32,P=0.0006),狼疮肾炎患者高于非活动期患者(4.0 μg/ml vs 2.3 μg/ml,P<0.001)。重组LGALS3BP和SLE患者血小板释放物增强巨噬细胞促炎细胞因子产生。

要点

  • SLE患者血小板LGALS3BP表达增加,倍数变化4.0,校正P=6.02×10⁻¹¹。
  • 循环LGALS3BP与SLE疾病活动指数相关(r=0.32,P=0.0006)。
  • 狼疮肾炎患者循环LGALS3BP高于非活动期患者(4.0 μg/ml vs 2.3 μg/ml,P<0.001)。

核心结论

  • 血小板通过分泌促炎LGALS3BP参与SLE发病,LGALS3BP是SLE临床活动性的新型生物标志物。

研究设计与样本

  • 对54例SLE患者和18名年龄、性别、种族/民族匹配的健康对照的血小板进行RNA测序,并检测血小板释放物和循环血清中LGALS3BP水平。

主要发现

  • SLE患者血小板LGALS3BP表达增加(倍数变化4.0,校正P=6.02×10⁻¹¹)。
  • 血小板释放的LGALS3BP与循环LGALS3BP高度相关(R=0.69,P<0.0001)。
  • 循环LGALS3BP与SLE疾病活动指数严重程度相关(r=0.32,P=0.0006)。
  • 狼疮肾炎患者循环LGALS3BP高于非活动性疾病患者(4.0 μg/ml vs 2.3 μg/ml,P<0.001)。
  • 干扰素-α以剂量依赖性方式诱导巨幼红细胞白血病细胞系(MEG-01)中LGALS3BP转录和翻译。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Platelets are mediators of inflammation with immune effector cell properties and have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). This study investigated the role of platelet-associated lectin, galactoside-binding, soluble 3 binding protein (LGALS3BP) as a mediator of inflammation in SLE and as a potential biomarker associated with clinical phenotypes. METHODS: We performed RNA sequencing on platelets from patients with SLE (n = 54) and on platelets from age-, sex-, and race/ethnicity-matched healthy controls (n = 18) and measured LGALS3BP levels in platelet releasate and in circulating serum. We investigated the association between LGALS3BP levels and the prevalence, disease severity, and clinical phenotypes of SLE and studied platelet-mediated effects on myeloid inflammation. RESULTS: Platelets from patients with SLE exhibited increased expression of LGALS3BP (fold change 4.0, adjusted P = 6.02 × 10-11 ). Platelet-released LGALS3BP levels were highly correlated with circulating LGALS3BP (R = 0.69, P < 0.0001), and circulating LGALS3BP levels were correlated with the severity of disease according to the SLE Disease Activity Index (r = 0.32, P = 0.0006). Specifically, circulating LGALS3BP levels were higher in SLE patients with lupus nephritis than in patients with inactive disease (4.0 μg/ml versus 2.3 μg/ml; P < 0.001). Interferon-α induced LGALS3BP transcription and translation in a megakaryoblastic cell line (MEG-01) in a dose-dependent manner. Recombinant LGALS3BP and platelet releasates from SLE patients enhanced proinflammatory cytokine production by macrophages. CONCLUSIONS: Our results support that platelets act as potent effector cells that contribute to the pathogenesis of SLE by secreting proinflammatory LGALS3BP, which also represents a novel biomarker of SLE clinical activity.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. El Bannoudi H, Cornwell M, Luttrell-Williams E, et al. Platelet LGALS3BP as a Mediator of Myeloid Inflammation in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2023. PMID: 36245285. doi:10.1002/art.42382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。